A heart transplant and a left ventricular assist device (LVAD) can be lifesaving when a patient has severe heart failure. LVADs continue to improve, however, heart transplant remains the gold standard therapy for end-stage heart failure. A new Michigan Medicine study finds that a change to Medicare policy surrounding heart transplants may lead to increased inequities in access to transplants for patients with heart failure.
